Engineered Extracellular Vesicles Deliver IL-2 and Antibodies for Precision Immunotherapy

Researchers are engineering extracellular vesicles (EVs) as precision delivery vehicles for immunotherapies, with two recent efforts demonstrating targeted delivery of IL-2 for autoimmune diseases and cancer, and antibody-loaded exosome nanovesicles for inflammatory bowel disease (IBD).

Interleukin-2 (IL-2) is a pleiotropic cytokine that plays a central role in immune regulation by maintaining the balance between immunosuppressive regulatory T cells (Tregs) and immuno-activating effector T cells. Systemic administration of IL-2 has demonstrated therapeutic potential; however, dose-dependent variance in affect increases challenges with clinical application. Low-dose IL-2 preferentially expands Tregs and high-dose IL-2 activates effector T cells and natural killer (NK) cells, while often resulting in off-target immune activation and severe toxicities such as cytokine storm. The short in vivo half-life of IL-2 leads to rapid renal clearance requiring clinical high-dose administration leading to severe toxicities. Currently there are no precision delivery platforms that enable targeted IL-2 activation while minimizing systemic toxicity.

To address these limitations, researchers are engineering extracellular vesicles as a precision delivery vehicle for IL-2. EVs are naturally secreted, membrane-bound nanoparticles released by all cell types and offer several advantages for therapeutic delivery, including protection of cargo from enzymatic degradation, tissue-specific targeting potential, and high biocompatibility. A microfluidic electroporation platform enables controlled and efficient IL-2 loading into EVs. This system utilizes water-in-oil droplet encapsulation of EVs, which are electroporated as they flow through parallel microfabricated metal electrodes. The non-conductive oil phase electrically isolates individual aqueous droplets, allowing for consistent, short-pulsed voltage delivery to each EV-containing droplet while minimizing bulk heating and membrane damage. This architecture enables precise tuning of electroporation conditions to maximize cargo encapsulation while preserving EV integrity. Other common EV loading methods such as lipofection, sonication and freeze thaw can cause changes in natural EV properties such as size, concentration and morphology, which are not observed with the microfluidic technique. The method additionally allows continuous flow scalability of loading, an exceptional benefit for clinical translation.

To optimize IL-2 loading, researchers systematically varied IL-2 concentrations from 1 to 200 µg IL-2/mL and EV concentrations from 10^9 to 10^11 EV/mL to identify saturation conditions that yield maximal loading efficiency. The most feasible efficiency was found at 10^11 EV/mL and 105 µg IL-2/mL, giving overall loading of 4±0.1 µg/mL IL-2. Functional delivery of EV-encapsulated IL-2 was tested from 3.125 to 200 IU IL-2/mL on IL-2-dependent CTLL-2 cell line, where cellular uptake and viability confirmed bioactivity of the delivered cytokine when in EVs. Ongoing studies are evaluating dose-dependent activation of distinct T-cell populations across time by quantifying STAT5 signaling pathway activation to determine differing optimal immunomodulatory dosing for both autoimmune diseases such as type 1 diabetes and cancers such as colorectal cancer. Future work will assess biodistribution and therapeutic efficacy of orally administered EV-IL-2 in both wild-type and IL-2 knockout mouse models, leveraging gut-mediated uptake pathways for immune modulation.

In a separate advancement, scientists have engineered exosome nanovesicles designed to deliver therapeutic antibodies directly to sites of inflammation in the gastrointestinal tract. The approach is detailed in an upcoming publication in Nature Communications. Inflammatory bowel disease, encompassing Crohn’s disease and ulcerative colitis, has long posed immense challenges due to its chronic, relapsing nature and the difficulty in precisely targeting inflamed tissues without systemic side effects. Traditional antibody therapies often suffer from poor bioavailability, rapid clearance from the bloodstream, and off-target effects. The new strategy employs engineered exosome nanovesicles—tiny, lipid-bilayer vesicles naturally secreted by cells and capable of crossing biological barriers—to ferry antibodies with precision. The cornerstone of this technology lies in the bioengineering of exosomes derived from immune cells, tailored to encapsulate monoclonal antibodies against key inflammatory mediators implicated in IBD pathogenesis. These nanovesicles exhibit exceptional stability in the hostile environment of the gastrointestinal tract, enabling the antibodies to survive enzymatic degradation and reach the inflamed mucosa intact. Upon arrival, the exosomes engage with target cells through receptor-mediated mechanisms, facilitating the intracellular delivery of antibodies to modulate aberrant immune responses driving disease progression.

The researchers used cutting-edge molecular techniques to functionalize the exosome surfaces with ligands that selectively bind to adhesion molecules overexpressed in the inflamed intestinal endothelium. This active targeting mechanism enhances the accumulation of therapeutic antibodies exactly where they are needed, minimizing off-target delivery and systemic immunosuppression. The resultant pharmacokinetic profile showed prolonged retention of the antibody payload in diseased tissues, translating to improved efficacy in preclinical IBD models. In rigorous in vivo experiments involving murine models of colitis, treatment with these engineered exosome nanovesicles led to notable reductions in inflammatory cytokine levels, diminished mucosal ulceration, and restoration of intestinal barrier integrity. Further mechanistic studies uncovered that the delivery of antibodies via engineered exosomes not only neutralizes pro-inflammatory cytokines but also reprograms local immune cell populations. This reprogramming shifts macrophage polarization from a pro-inflammatory M1 phenotype to a regulatory M2 phenotype, fostering an environment conducive to tissue repair and immune homeostasis.

The versatility of this platform opens avenues for application beyond antibody delivery. By customizing the cargo payload, researchers envision the potential encapsulation of nucleic acids such as siRNAs or therapeutic proteins, enabling combinatorial therapies in a single nanovesicle formulation. The scalability of exosome production was addressed through the development of bioreactor systems optimized for mass culture of donor cells, ensuring adherence to good manufacturing practices (GMP), a critical step toward clinical translation. Coupled with standardized purification protocols and thorough characterization by nanoparticle tracking analysis, electron microscopy, and flow cytometry, the study lays a comprehensive foundation for clinical application.